Clinical outcomes of patients with COVID-19 and inflammatory rheumatic diseases receiving biological/targeted therapy

Clinical outcomes of patients with COVID-19 and inflammatory rheumatic diseases receiving biological/targeted therapy

BACKGROUND: Anti-cytokine treatments are used in the treatment of severe COVID-19. Other studies have shown statistical significance with TNF inhibitors but not with other biological/targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARD). OBJECTIVES: Compare the rate of severe acute r...

Full description

Bibliographic Details
Main Authors:	Özlem Pehlivan, Tutku Aydin
Format:	Article
Language:	English
Published:	King Faisal Specialist Hospital and Research Centre 2022-05-01
Series:	Annals of Saudi Medicine
Online Access:	http://www.annsaudimed.net/doi/10.5144/0256-4947.2022.155

Similar Items

Comparisons of Clinical Features and Outcomes of COVID-19 between Patients with Pediatric Onset Inflammatory Rheumatic Diseases and Healthy Children
by: Fatih Haslak, et al.
Published: (2022-04-01)

Impact of Immunomodulatory Therapy on COVID-19 Vaccine Response in Patients with Autoimmune Inflammatory Rheumatic Diseases
by: Ruth Xian Lynn Yap, et al.
Published: (2024-03-01)

Interleukin-6 inhibitors: from the therapy of immuno-inflammatory rheumatic diseases to use in COVID-19
by: N. V. Muravyeva, et al.
Published: (2022-07-01)

COVID-19 presentation and outcomes in patients with inflammatory rheumatic and musculoskeletal diseases receiving IL6-receptor antagonists prior to SARS-CoV-2 infection
by: Cloé Comarmond, et al.
Published: (2023-01-01)

TARGETED THERAPY AND INFECTIONS IN RHEUMATIC DISEASES
by: B. S. Belov, et al.
Published: (2016-12-01)

The Recent Outbreak of COVID-19 in China During the Omicron Variant Predominance: Clinical Features and Outcomes in Patients with Autoimmune Inflammatory Rheumatic Diseases
by: Yan Geng, et al.
Published: (2023-06-01)

Editorial: Autoimmune and inflammatory rheumatic diseases: Identifying biomarkers of response to therapy with biologics: Volume II
by: Anna Lisa Giuliani, et al.
Published: (2023-02-01)

The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs: a Swedish nationwide study (COVID-19-REUMA)
by: Martina Frodlund, et al.
Published: (2024-04-01)

Outcome of COVID-19 in patients with rheumatic and inflammatory diseases treated with mycophenolic acid: data from the French RMD COVID-19 cohort
by: Eric Hachulla, et al.
Published: (2022-09-01)

How Did the Two Years of the COVID-19 Pandemic Affect the Outcomes of the Patients with Inflammatory Rheumatic Diseases in Lithuania?
by: Jolanta Dadonienė, et al.
Published: (2023-02-01)

Immunosuppressive therapy selectively modulates B‐cell responses in patients with rheumatic and musculoskeletal diseases receiving the inactivated COVID‐19 vaccine
by: Rui Li, et al.
Published: (2023-06-01)

Evaluation of Predictors Associated with COVID-19 Pneumonia in Rheumatic Patients Using Biological or Targeted Therapies: Results from a Tertiary Center in Turkey
by: Yasemin Ozden Eldemir, et al.
Published: (2023-11-01)

INTERLEUKIN-17 IS A NEW TARGET FOR ANTI-CYTOKINE THERAPY OF IMMUNE INFLAMMATORY RHEUMATIC DISEASES
by: Evgeny Lvovich Nasonov, et al.
Published: (2013-12-01)

The First Effect of COVID-19 Pandemic on Starting Biological Disease Modifying Anti-Rheumatic Drugs: Outcomes from the TReasure Real-Life Database
by: Nilüfer Alpay Kanıtez, et al.
Published: (2022-10-01)

Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases
by: Yi-Qing Zheng, et al.
Published: (2022-10-01)

Infections after Biologic Agent Therapy in rheumatic diseases
by: S. Kinikli, et al.
Published: (2014-04-01)

Biologic agents in immune-mediated inflammatory rheumatic diseases: current state of the art and clinical practice in Romania
by: A. Balanesc, et al.
Published: (2017-09-01)

Clinical Outcomes of COVID‑19 Patients with Rheumatic and Musculoskeletal Diseases: A Single Centre Cohort Study
by: Carolina Mazeda, et al.
Published: (2023-02-01)

Multisystem inflammatory syndrome in children during the COVID-19 waves: data from the Juvenile Inflammatory Rheumatism cohort
by: Robin Kechiche, et al.
Published: (2023-05-01)

COVID-19 Vaccine Hesitancy among Patients with Inflammatory Bowel Disease Receiving Biologic Therapies in Kuwait: A Cross-Sectional Study
by: Mohammad Shehab, et al.
Published: (2021-12-01)

The spectrum of inflammatory rheumatic disorders.
by: Walker-Bone, K, et al.
Published: (2000)

Inflammatory markers in rheumatic diseases
by: A. S. Avdeeva
Published: (2022-12-01)

Anti-Drug Antibodies in the Biological Therapy of Autoimmune Rheumatic Diseases
by: Oscar Pizano-Martinez, et al.
Published: (2023-05-01)

Tuberculin test conversion in patients with chronic inflammatory arthritis receiving biological therapy
by: Osvaldo Luis Cerda, et al.
Published: (2019-01-01)

Are immunosuppressant related to unfavorable outcomes in patients COVID-19 with autoimmune rheumatic disease?: A review of clinical evidence
by: Oki Nugraha Putra, et al.
Published: (2022-01-01)

PROSPECTS FOR ANTI-B-CELL THERAPY IN IMMUNO-INFLAMMATORY RHEUMATIC DISEASES
by: e L. Nasonov, et al.
Published: (2019-12-01)

Experience in managing psoriasis patients receiving targeted therapy during the COVID-19 pandemic
by: N. N. Potekaev, et al.
Published: (2020-10-01)

Perceptions towards biologic and biosimilar therapy of patients with rheumatic and gastroenterological conditions
by: Thomas Khoo, et al.
Published: (2022-12-01)

Particularities regarding Clinical-biological and Evolutive Parameters of Immune-mediated Rheumatic Diseases in Patients with COVID-19 – systematic literature review
by: Andreea Iulia Trandafir, et al.
Published: (2023-06-01)

COVID‐19 Hospitalization Outcomes Among Patients With Autoimmune Rheumatic Diseases in the United States
by: Ahmad Khalaf, et al.
Published: (2023-07-01)

Radiological and inflammatory outcome in severe covid-19 patients received tocilizumab versus high dose of methylprednisolone
by: Asmaa kamel, et al.
Published: (2022-10-01)

CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases
by: Kevin Chevalier, et al.
Published: (2023-03-01)

Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity
by: E. L. Nasonov, et al.
Published: (2020-09-01)

Inflammatory and Hypercoagulable Biomarkers and Clinical Outcomes in COVID-19 Patients
by: Hiroki Kitakata, et al.
Published: (2021-07-01)

Clinical Outcome of Rheumatic Mitral Valve Repair and Replacement Surgery in Indonesia; A Comparison with Non-Rheumatic Aetiology
by: Amiliana Mardiani Soesanto, et al.
Published: (2024-01-01)

Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis
by: Hong Ki Min, et al.
Published: (2022-11-01)

Characteristic clinical features of rheumatic patients with COVID-19 infection in mataria teaching hospital
by: Wessam Eissa Hamed, et al.
Published: (2022-01-01)

Therapy with non-steroidal anti-inflammatory drugs and the quality of life of patients with rheumatic diseases
by: E. Yu. Polishchuk, et al.
Published: (2022-02-01)

COVID-19 Clinical Features and Outcome in Italian Patients Treated with Biological Drugs Targeting Type 2 Inflammation
by: Giada Sambugaro, et al.
Published: (2024-03-01)

Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry
by: Bente Glintborg, et al.
Published: (2022-11-01)